| Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia KG Roberts, Y Li, D Payne-Turner, RC Harvey, YL Yang, D Pei, ... New England journal of medicine 371 (11), 1005-1015, 2014 | 1475 | 2014 |
| New brain tumor entities emerge from molecular classification of CNS-PNETs D Sturm, BA Orr, UH Toprak, V Hovestadt, DTW Jones, D Capper, M Sill, ... Cell 164 (5), 1060-1072, 2016 | 824 | 2016 |
| Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis EM Thompson, T Hielscher, E Bouffet, M Remke, B Luu, S Gururangan, ... The Lancet Oncology 17 (4), 484-495, 2016 | 355 | 2016 |
| Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma H Nikbakht, E Panditharatna, LG Mikael, R Li, T Gayden, M Osmond, ... Nature communications 7, 2016 | 239 | 2016 |
| Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors J Torchia, B Golbourn, S Feng, KC Ho, P Sin-Chan, A Vasiljevic, ... Cancer Cell 30 (6), 891-908, 2016 | 224 | 2016 |
| Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns AS Moore, A Faisal, DG De Castro, V Bavetsias, C Sun, B Atrash, ... Leukemia 26 (7), 1462-1470, 2012 | 143 | 2012 |
| Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias AS Moore, J Blagg, S Linardopoulos, ADJ Pearson Leukemia 24 (4), 671-678, 2010 | 111 | 2010 |
| Vincristine: Can its therapeutic index be enhanced? A Moore, R Pinkerton Pediatric blood & cancer 53 (7), 1180-1187, 2009 | 107 | 2009 |
| Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy C Bruedigam, FO Bagger, FH Heidel, CP Kuhn, S Guignes, A Song, ... Cell Stem Cell 15 (6), 775-790, 2014 | 89 | 2014 |
| Optimization of Imidazo[4,5-b]pyridine-Based Kinase Inhibitors: Identification of a Dual FLT3/Aurora Kinase Inhibitor as an Orally Bioavailable Preclinical … V Bavetsias, S Crumpler, C Sun, S Avery, B Atrash, A Faisal, AS Moore, ... Journal of medicinal chemistry 55 (20), 8721-8734, 2012 | 83 | 2012 |
| Vincristine pharmacodynamics and pharmacogenetics in children with cancer: A limited‐sampling, population modelling approach AS Moore, R Norris, G Price, T Nguyen, M Ni, R George, K van Breda, ... Journal of paediatrics and child health 47 (12), 875-882, 2011 | 69 | 2011 |
| Novel therapies for children with acute myeloid leukaemia AS Moore, PR Kearns, S Knapper, ADJ Pearson, CM Zwaan Leukemia 27 (7), 1451-1460, 2013 | 62 | 2013 |
| Vincristine sulfate liposomal injection for acute lymphoblastic leukemia (vol 8, pg 4361, 2013) STA Raj, AM Smith, AS Moore INTERNATIONAL JOURNAL OF NANOMEDICINE 8, 4705-4705, 2013 | 51* | 2013 |
| Vincristine sulfate liposomal injection for acute lymphoblastic leukemia [Corrigendum] TA Soosay Raj, AM Smith, AS Moore International journal of nanomedicine 8, 4705, 2013 | 50* | 2013 |
| Vincristine sulfate liposomal injection for acute lymphoblastic leukemia TAS Raj, AM Smith, AS Moore International journal of nanomedicine 8, 4361, 2013 | 50 | 2013 |
| Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors. AM Smith, MD Dun, EM Lee, C Harrison, R Kahl, H Flanagan, N Panicker, ... Oncotarget 7 (30), 47465, 2016 | 48 | 2016 |
| BIRC5 (survivin) splice variant expression correlates with refractory disease and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group AS Moore, TA Alonzo, RB Gerbing, BJ Lange, NA Heerema, J Franklin, ... Pediatric blood & cancer 61 (4), 647-652, 2014 | 37 | 2014 |
| EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia S Charmsaz, F Al-Ejeh, T Yeadon, KJ Miller, F Smith, B Stringer, ... Leukemia, 2016 | 36 | 2016 |
| Haemopoietic stem cell transplantation for children in Australia and New Zealand, 1998-2006: a report on behalf of the Australasian Bone Marrow Transplant Recipient Registry … AS Moore, PJ Shaw, AR Hallahan, TL Carter, T Kilo, I Nivison-Smith, ... Medical Journal of Australia 190 (3), 121, 2009 | 30 | 2009 |
| EphA2 is a therapy target in EphA2-positive leukemias but is not essential for normal hematopoiesis or leukemia S Charmsaz, K Beckett, FM Smith, C Bruedigam, AS Moore, F Al-Ejeh, ... PloS one 10 (6), e0130692, 2015 | 27 | 2015 |
